miR‑135b inhibits tumour metastasis in prostate cancer by targeting STAT6

Wang,Ning; Tao,Liangjun; Zhong,Huan; Zhao,Sihai; Yu,Ying; Yu,Bin; Chen,Xiaonong; Gao,Jianguo; Wang,Rongjiang

doi:10.3892/ol.2015.3970

miR‑135b inhibits tumour metastasis in prostate cancer by targeting STAT6

Authors:
- Ning Wang
- Liangjun Tao
- Huan Zhong
- Sihai Zhao
- Ying Yu
- Bin Yu
- Xiaonong Chen
- Jianguo Gao
- Rongjiang Wang
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Huzhou Teachers College, Huzhou, Zhejiang 313000, P.R. China, Department of Urology and Institute of Prostatic Diseases, The Affiliated Wuhu No. 2 People's Hospital of Wannan Medical College, Wuhu, Anhui 241000, P.R. China
Published online on: November 25, 2015 https://doi.org/10.3892/ol.2015.3970
Pages: 543-550
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are small non‑coding RNAs that participate in several cellular functions and tumour progression. A previous microarray study demonstrated that miR‑135b is downregulated in prostate cancer (PCa) cells, but the role and molecular mechanism of miR‑135b in the regulation of tumour metastasis remain to be elucidated. In the present study, significant downregulation of miR‑135b in PCa tissues, compared with noncancerous tissues, was detected by reverse transcription‑quantitative polymerase chain reaction. Furthermore, the expression of miR‑135b was demonstrated to be associated with the pathological stage and the levels of total and free prostate‑specific antigen (PSA) in PCa cells. In addition, signal transducer and activator of transcription 6 (STAT6) was identified as a target of miR‑135b in PCa cells by luciferase activity and western blot assays. The upregulation of miR‑135b in PCa cells led to reduced expression of STAT6 in the cytoplasm and nucleus of these cells, while the overexpression of miR‑135b and knockdown of STAT6 were able to inhibit the migration and invasion abilities of PCa cells in vitro. Therefore, the results of the present study indicate that miR‑135b suppresses tumour metastasis by targeting STAT6.

View Figures

View References

1	Pflug BR, Pecher SM, Brink AW, Nelson JB and Foster BA: Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model. Prostate. 57:245–254. 2003. View Article : Google Scholar : PubMed/NCBI
2	Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DS, et al: A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 66:550–560. 2014. View Article : Google Scholar : PubMed/NCBI
3	Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45. 2001. View Article : Google Scholar : PubMed/NCBI
4	Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, et al: Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res. 11:6823–6834. 2005. View Article : Google Scholar : PubMed/NCBI
5	Valencia-Sanchez MA, Liu J, Hannon GJ and Parker R: Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
6	Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
7	Ventura A and Jacks T: MicroRNAs and cancer: Short RNAs go a long way. Cell. 136:586–591. 2009. View Article : Google Scholar : PubMed/NCBI
8	Iorio MV and Croce CM: MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol. 27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
9	Baranwal S and Alahari SK: miRNA control of tumour cell invasion and metastasis. Int J Cancer. 126:1283–1290. 2010.PubMed/NCBI
10	Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M and García-Foncillas J: Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoural tissues. Mol Cancer. 5:292006. View Article : Google Scholar : PubMed/NCBI
11	Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G and Kerin MJ: MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 11:R272009. View Article : Google Scholar : PubMed/NCBI
12	Bhattacharya A, Ziebarth JD and Cui Y: Systematic analysis of microRNA targeting impacted by small insertions and deletions in human genome. PLoS One. 7:e461762012. View Article : Google Scholar : PubMed/NCBI
13	Hebenstreit D, Wirnsberger G, Horejs-Hoeck J and Duschl A: Signaling mechanisms, interaction partners and target genes of STAT6. Cytokine Growth Factor Rev. 17:173–188. 2006. View Article : Google Scholar : PubMed/NCBI
14	Rothstein TL: Inducible resistance to Fas-mediated apoptosis in B cells. Cell Res. 10:245–266. 2000. View Article : Google Scholar : PubMed/NCBI
15	Ansel KM, Djuretic I, Tanasa B and Rao A: Regulation of Th2 differentiation and Il4 locus accessibility. Annu Rev Immunol. 24:607–656. 2006. View Article : Google Scholar : PubMed/NCBI
16	Ni Z, Lou W, Lee SO, Dhir R, DeMiguel F, Grandis JR and Gao AC: Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma. J Urol. 167:1859–1862. 2002. View Article : Google Scholar : PubMed/NCBI
17	Li BH, Yang XZ, Li PD, Yuan Q, Liu XH, Yuan J and Zhang WJ: IL-4/Stat6 activities correlate with apoptosis and metastasis in colon cancer cells. Biochem Biophys Res Commun. 369:554–560. 2008. View Article : Google Scholar : PubMed/NCBI
18	Benekli M, Baer MR, Baumann H and Wetzler M: Signal transducer and activator of transcription proteins in leukemias. Blood. 101:2940–2954. 2003. View Article : Google Scholar : PubMed/NCBI
19	Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, Kapp U and Mak TW: Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 99:618–626. 2002. View Article : Google Scholar : PubMed/NCBI
20	Guiter C, Dusanter-Fourt I, Copie-Bergman C, Boulland ML, Le Gouvello S, Gaulard P, Leroy K and Castellano F: Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood. 104:543–549. 2004. View Article : Google Scholar : PubMed/NCBI
21	Melzner I, Bucur AJ, Brüderlein S, Dorsch K, Hasel C, Barth TF, Leithäuser F and Möller P: Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood. 105:2535–2542. 2005. View Article : Google Scholar : PubMed/NCBI
22	Bruns HA and Kaplan MH: The role of constitutively active Stat6 in leukemia and lymphoma. Crit Rev Oncol Hematol. 57:245–253. 2006. View Article : Google Scholar : PubMed/NCBI
23	Xu L, Tan AC, Naiman DQ, Geman D and Winslow RL: Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data. Bioinformatics. 21:3905–3911. 2005. View Article : Google Scholar : PubMed/NCBI
24	Lin CH, Jackson AL, Guo J, Linsley PS and Eisenman RN: Myc-regulated microRNAs attenuate embryonic stem cell differentiation. EMBO J. 28:3157–3170. 2009. View Article : Google Scholar : PubMed/NCBI
25	Nagel R, le Sage C, Diosdado B, van der Waal M, Oude Vrielink JA, Bolijn A, Meijer GA and Agami R: Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 68:5795–5802. 2008. View Article : Google Scholar : PubMed/NCBI
26	Liu CJ, Tsai MM, Hung PS, Kao SY, Liu TY, Wu KJ, Chiou SH, Lin SC and Chang KW: miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res. 70:1635–1644. 2010. View Article : Google Scholar : PubMed/NCBI
27	Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J and Nemunaitis J: MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther. 16:206–216. 2009.PubMed/NCBI
28	Östling P, Leivonen SK, Aakula A, Kohonen P, Mäkelä R, Hagman Z, Edsjö A, Kangaspeska S, Edgren H, Nicorici D, et al: Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res. 71:1956–1967. 2011. View Article : Google Scholar : PubMed/NCBI
29	Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M and Carinci F: MicroRNA expression profiling of oral carcinoma identifies new markers of tumour progression. Int J Immunopathol Pharmacol. 23:1229–1234. 2010.PubMed/NCBI
30	Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J and Galandiuk S: Plasma miR-21: A potential diagnostic marker of colorectal cancer. Ann Surg. 256:544–551. 2012. View Article : Google Scholar : PubMed/NCBI
31	Gaedcke J, Grade M, Camps J, Søkilde R, Kaczkowski B, Schetter AJ, Difilippantonio MJ, Harris CC, Ghadimi BM, Møller S, et al: The rectal cancer microRNAome-microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res. 18:4919–4930. 2012. View Article : Google Scholar : PubMed/NCBI
32	Xu XM, Qian JC, Deng ZL, Cai Z, Tang T, Wang P, Zhang KH and Cai JP: Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer. Oncol Lett. 4:339–345. 2012.PubMed/NCBI
33	Ma L and Weinberg RA: Micromanagers of malignancy: Role of microRNAs inregulating metastasis. Trends Genet. 24:448–456. 2008. View Article : Google Scholar : PubMed/NCBI
34	Khew-Goodall Y and Goodall GJ: Myc-modulated miR-9 makes more metastases. Nat Cell Biol. 12:209–211. 2010.PubMed/NCBI
35	Pang Y, Young CY and Yuan H: MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai). 42:363–369. 2010. View Article : Google Scholar : PubMed/NCBI
36	Lin SL, Chiang A, Chang D and Ying SY: Loss of mir-146a function in hormone-refractory prostate cancer. RNA. 14:417–424. 2008. View Article : Google Scholar : PubMed/NCBI
37	Calò V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N and Russo A: STAT proteins: From normal control of cellular events to tumorigenesis. J Cell Physiol. 197:157–168. 2003. View Article : Google Scholar : PubMed/NCBI
38	Schindler C and Darnell JE Jr: Transcriptional responses to polypeptide ligands: The JAK-STAT pathway. Annu Rev Biochem. 64:621–651. 1995. View Article : Google Scholar : PubMed/NCBI
39	Darnell JE Jr: STATs and gene regulation. Science. 277:1630–1635. 1997. View Article : Google Scholar : PubMed/NCBI
40	Das S, Roth CP, Wasson LM and Vishwanatha JK: Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate. 67:1550–1564. 2007. View Article : Google Scholar : PubMed/NCBI
41	Fukuda K, Fujitsu Y, Kumagai N and Nishida T: Characterization of the interleukin-4 receptor complex in human corneal fibroblasts. Invest Ophthalmol Vis Sci. 43:183–188. 2002.PubMed/NCBI
42	Ostrand-Rosenberg S, Grusby MJ and Clements VK: Cutting edge: STAT6-deficient mice have enhanced tumour immunity to primary and metastatic mammary carcinoma. J Immunol. 165:6015–6019. 2000. View Article : Google Scholar : PubMed/NCBI
43	Ostrand-Rosenberg S, Sinha P, Clements V, Dissanayake SI, Miller S, Davis C and Danna E: Signal transducer and activator of transcription 6 (Stat6) and CD1: Inhibitors of immunosurveillance against primary tumours and metastatic disease. Cancer Immunol Immunother. 53:86–91. 2004. View Article : Google Scholar : PubMed/NCBI